Valuation — not yet established
No valuation for Amunix Pharmaceuticals is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($117.0M) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for Amunix Pharmaceuticals
Create free account
No card required
Funding history
2 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Mar 2021 | Later Stage VC | $117.0M | ▮ | ▮ |
| Feb 2020 | Later Stage VC | $83.6M | ▮ | ▮ |
How Amunix Pharmaceuticals's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Amunix Pharmaceuticals, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has Amunix Pharmaceuticals raised?
- Amunix Pharmaceuticals has raised $117.0M in total funding across 2 recorded rounds.
- When did Amunix Pharmaceuticals last raise?
- Amunix Pharmaceuticals last raised in Mar 2021 (Later Stage VC), raising $117.0M.